PMID- 34714523
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211125
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 12
DP  - 2021 Dec
TI  - Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus 
      Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
PG  - 3217-3230
LID - 10.1007/s13300-021-01159-y [doi]
AB  - INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio 
      combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) 
      versus the FRC of insulin degludec plus liraglutide (iDegLira) and the 
      free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) 
      and basal insulin plus liraglutide (BI plus Lira). METHODS: The IQVIA Core 
      Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of 
      patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. 
      Initial clinical data for iGlarLixi were based on the randomized, controlled 
      LixiLan-L trial and the relative treatment effects for comparators were based on 
      an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), 
      LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived 
      from publicly available sources. Lifetime costs (in British Pound Sterling [ pound]) 
      and quality-adjusted life-years (QALYs) were predicted; net monetary benefit 
      (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay 
      threshold of  pound20,000. Extensive scenario and sensitivity analyses were conducted. 
      RESULTS: Estimated costs were lowest with iGlarLixi ( pound31,295) compared with iGlar 
      plus Dula ( pound38,790), iDegLira ( pound40,179), and BI plus Lira ( pound42,467). Total QALYs 
      gained were identical with iGlarLixi and iDegLira (8.438), and comparable with 
      iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive 
      versus all comparators ( pound10,603.86 vs. BI plus Lira;  pound7,466.24 vs. iGlar plus 
      Dula;  pound8.874.11 vs. iDegLira). CONCLUSION: In patients with T2DM with suboptimal 
      glycemic control on basal insulin, iGlarLixi provides very similar outcomes and 
      substantial cost savings, compared with other fixed and free combinations of 
      insulins plus glucagon-like peptide-1 receptor agonists.
CI  - (c) 2021. The Author(s).
FAU - McCrimmon, Rory J
AU  - McCrimmon RJ
AD  - School of Medicine, University of Dundee, Dundee, UK.
FAU - Falla, Edel
AU  - Falla E
AD  - IQVIA, Real-World Solutions, London, UK.
FAU - Sha, Jo Zhou
AU  - Sha JZ
AD  - IQVIA, Real-World Solutions, London, UK.
FAU - Alsaleh, Abdul Jabbar Omar
AU  - Alsaleh AJO
AD  - Department of Economics, University of Bologna, Bologna, Italy.
FAU - Lew, Elisheva
AU  - Lew E
AD  - Sanofi, Paris, France. Elisheva.Lew@sanofi.com.
FAU - Hudson, Richard
AU  - Hudson R
AD  - Sanofi, Reading, UK.
FAU - Baxter, Mike
AU  - Baxter M
AD  - Sanofi, Reading, UK.
FAU - Palmer, Karen
AU  - Palmer K
AD  - Sanofi, Reading, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20211029
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8586275
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Cost-utility
OT  - Dulaglutide
OT  - GLP-1 receptor agonist
OT  - Liraglutide
OT  - Type 2 diabetes mellitus
OT  - United Kingdom
OT  - iDegLira
OT  - iGlarLixi
EDAT- 2021/10/30 06:00
MHDA- 2021/10/30 06:01
PMCR- 2021/10/29
CRDT- 2021/10/29 12:30
PHST- 2021/08/04 00:00 [received]
PHST- 2021/09/18 00:00 [accepted]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2021/10/30 06:01 [medline]
PHST- 2021/10/29 12:30 [entrez]
PHST- 2021/10/29 00:00 [pmc-release]
AID - 10.1007/s13300-021-01159-y [pii]
AID - 1159 [pii]
AID - 10.1007/s13300-021-01159-y [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Dec;12(12):3217-3230. doi: 10.1007/s13300-021-01159-y. Epub 
      2021 Oct 29.